Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Nova Mentis to Present PromisingPsilocybin Microdose Dataat 18th NFXF International Fragile X Conference Vancouver, British Columbia – July 11, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it will be discussing the therapeutic
Read More »
July 11, 2022
Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Vancouver, British Columbia – June 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it will be presenting at the H.C. Wainwright 1st Annual Mental
Read More »
June 22, 2022
Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
mRNA Diagnostic Index to Measure Drug Treatment Response Vancouver, British Columbia – June 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its
Read More »
June 16, 2022
Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay
Vancouver, British Columbia – June 09, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central
Read More »
June 9, 2022
Nova Mentis Receives Controlled Substances Export Approval From The U.S DEA For The Company’s Proprietary Psilocybin Drug NM 1001
Vancouver, British Columbia – June 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it received the required controlled substances export approval from the U.S. Drug
Read More »
June 7, 2022
Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Vancouver, British Columbia – May 12, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to welcome John Molinaro, a Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy, to its Scientific
Read More »
May 12, 2022